2402, 2020

Biotech with Anxiety Drug Lands Funding

Categories: Press Coverage, Uncategorized|Tags: , , |

DRUGS: $15.5M; XANAX IMPROVEMENT? Biotech with Anxiety Drug Lands Funding By Jessie Yount Orange Country Business Journal Monday, February 24, 2020 An effort to develop a new and improved version of an anti-anxiety drug—never commercialized in the U.S.—is underway in Newport Beach. Gaba Therapeutics Inc. has developed and patented a [...]

1401, 2020

GABA Therapeutics Commences Phase I Study in Etifoxine – Melbourne Australia

Categories: Press Coverage, Uncategorized|

Today, GABA Therapeutics commenced dosing for its Phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia – right on schedule. The Phase I, two-stage, double-blind, placebo-controlled single and multiple dose study will evaluate the pharmacokinetics, pharmacodynamics, and safety of oral etifoxine in up to 34 normal healthy [...]

2711, 2019

GABA Therapeutics Receives Approval to Begin Phase I Clinical Trials

Categories: Press Coverage, Uncategorized|

We are pleased to provide some positive updates. Inaugural Board Meeting The company held its first Board of Directors meeting in San Francisco in early November. Attendees included (left to right): Srini Rao M.D., Ph.D, Chief Medical Officer, GABA Therapeutics Ian Massey, D.Phil, CEO and Director, GABA Therapeutics Richard [...]

2009, 2019

GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders

Categories: Press Coverage, Press Release|

NEWPORT BEACH, Calif. and BERLIN, Sept. 20, 2019 /PRNewswire/ -- Today, GABA Therapeutics, a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences, a global biotech company builder working on paradigm shifting interventions for unmet needs in the mental health space, announced a partnership to develop a novel compound that promises [...]